SLC5A2 and chronic kidney disease: Due to consistent treatment effects of GLP-1 receptor agonists and SGLT2 inhibitors on major adverse cardiovascular events, and of SGLT2 inhibitors on renal endpoints with and without concomitant metformin use [76, 77], recent concepts have promoted the use of GLP1-receptor agonists and SGLT2 inhibitors in subjects with T2DM and CKD regardless of metformin administration [78].